Identification of a β-casein-like peptide in breast nipple aspirate fluid that is associated with breast cancer

Biomarkers in Medicine

Volumn 3, Issue 5, 2009, Pages 577-588

  Sauter, Edward R ^a   Davis, Wade ^b   Qin, Wenyi ^a   Scanlon, Sarah ^b   Mooney, Brian ^b   Bromert, Karen ^b   Folk, William R ^b  

^a UNIVERSITY OF NORTH DAKOTA SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

^b UNIVERSITY OF MISSOURI   (United States)

Author keywords

Biomarker; Breast cancer; Early detection; Nipple aspirate fluid; Proteomics

Indexed keywords

BETA CASEIN LIKE PEPTIDE; TUMOR MARKER; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BREAST BIOPSY; BREAST CANCER; CELL STRUCTURE; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC VALUE; ELECTROSPRAY MASS SPECTROMETRY; FEMALE; HUMAN; HUMAN TISSUE; IMMOBILIZED METAL AFFINITY CHROMATOGRAPHY; NIPPLE ASPIRATION; PROTEIN EXPRESSION; PROTEOMICS; SENSITIVITY AND SPECIFICITY; SURFACE ENHANCED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY;

EID: 70450230692     PISSN: 17520363     EISSN: None     Source Type: Journal    
DOI: 10.2217/bmm.09.46     Document Type: Article

References (26)

1. Fahy BN, Bold RJ, Schneider PD, Khatri V, Goodnight JE Jr: Cost-benefit analysis of biopsy methods for suspicious mammographic lesions; discussion 994-5. Arch. Surg. 136(9), 990-994 (2001).
2. Lehman CD, Gatsonis C, Kuhl CK et al.: MRI evaluation of the contralateral breast in women with recently diagnosed breast cancer. N. Engl. J. Med. 356(13), 1295-1303 (2007).
3. Whelan LC, Power KA, McDowell DT, Kennedy J, Gallagher WM: Applications of SELDI-MS technology in oncology. J. Cell. Mol. Med. 12(5A), 1535-1547 (2008).
4. Sauter ER, Shan S, Hewett JE, Speckman P, Du Bois GC: Proteomic analysis of nipple aspirate fluid using SELDI-TOF-MS. Int. J. Cancer 114(5), 791-796 (2005).
5. Sauter ER, Zhu W, Fan XJ, Wassell RP, Chervoneva I, Du Bois GC: Proteomic analysis of nipple aspirate fluid to detect biologic markers of breast cancer. Br. J. Cancer 86(9), 1440-1443 (2002).
6. He J, Gornbein J, Shen D et al.: Detection of breast cancer biomarkers in nipple aspirate fluid by SELDI-TOF and their identification by combined liquid chromatography-tandem mass spectrometry. Int. J. Oncol. 30(1), 145-154 (2007).
7. Noble JL, Dua RS, Coulton GR, Isacke CM, Gui GP: A comparative proteinomic analysis of nipple aspiration fluid from healthy women and women with breast cancer. Eur. J. Cancer 43(16), 2315-2320 (2007).
8. Paweletz CP, Trock B, Pennanen M et al.: Proteomic patterns of nipple aspirate fluids obtained by SELDI-TOF: potential for new biomarkers to aid in the diagnosis of breast cancer. Dis. Markers 17(4), 301-307 (2001).
9. Pawlik TM, Fritsche H, Coombes KR et al.: Significant differences in nipple aspirate fluid protein expression between healthy women and those with breast cancer demonstrated by time-of-flight mass spectrometry. Breast Cancer Res. Treat. 89(2), 149-157 (2005).
10. Eberl MM, Fox CH, Edge SB, Carter CA, Mahoney MC: BI-RADS classification for management of abnormal mammograms. J. Am. Board Fam. Med. 19(2), 161-164 (2006).
11. American College of Radiology: BI-RADS™ (2nd Edition). American College of Radiology, VA, USA (1995).
12. Sauter ER, Wagner-Mann C, Ehya H, Klein-Szanto A: Biologic markers of breast cancer in nipple aspirate fluid and nipple discharge are associated with clinical findings. Cancer Detect. Prev. 31(1), 50-58 (2007).
13. Agurs-Collins T, Adams-Campbell LL, Kim KS, Cullen KJ: Insulin-like growth factor-1 and breast cancer risk in postmenopausal African-American women. Cancer Detect. Prev. 24(3), 199-206 (2000).
14. Sauter ER, Ehya H, Schlatter L, MacGibbon B: Ductoscopic cytology to detect breast cancer. Cancer J. 10(1), 33-41; discussion 15-36 (2004).
15. Sauter ER, Ross E, Daly M et al.: Nipple aspirate fluid: a promising non-invasive method to identify cellular markers of breast cancer risk. Br. J. Cancer 76(4), 494-501 (1997).
16. Li X, Gentlemen R, Lu X et al.: SELDI-TOF Mass Spectrometry Protein Data. Springer, NY, USA (2005).
17. Mani DR, Gillette M: Proteomic Data Analysis: Pattern Recognition for Medical Diagnosis and Biomarker Discovery. IEE Press, NJ, USA (2004).
18. Gentlemen RC, Vandal AC: Computational algorithms for censored data problems using intersection graphs. J. Comput. Graph. Stat. 10, 403-421 (2001).
19. Yasui Y, Pepe M, Thompson ML et al.: A data-analytic strategy for protein-biomarker discovery: profiling of high-dimensional proteomic data for cancer detection. Biostatistics 4, 449-463 (2003).
20. Coombes KR, Koomen JM, Baggerly KA, Morris JS, Kobayashi R: Understanding the characteristics of mass spectrometry data through the use of simulation. Cancer Informatics 1, 41-52 (2005).
21. Efron B: Estimating the error rate of a prediction rule: improvement on crossvalidation. J. Am. Stat. Assoc. 78, 316-330 (1983).
22. Meisel H: Biochemical properties of peptides encrypted in bovine milk proteins. Curr. Med. Chem. 12(16), 1905-1919 (2005).
23. Kampa M, Loukas S, Hatzoglou A, Martin P, Martin PM, Castanas E: Identification of a novel opioid peptide (Tyr-Val-Pro-Phe-Pro) derived from human α S1 casein (α S1-casomorphin, and a S1-casomorphin amide). Biochem. J. 319(Pt 3), 903-908 (1996).
24. Leiting B, Pryor KD, Wu JK et al.: Catalytic properties and inhibition of proline-specific dipeptidyl peptidases II, IV and VII. Biochem. J. 371(Pt 2), 525-532 (2003).
25. Riedl CC, Ponhold L, Flory D et al.: Magnetic resonance imaging of the breast improves detection of invasive cancer, preinvasive cancer, and premalignant lesions during surveillance of women at high risk for breast cancer. Clin. Cancer Res. 13(20), 6144-6152 (2007).
26. Matrix Science. www.matrixscience.com